SCHEMBL3016578

SCHEMBL3016578

CCc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4c(F)c(Br)cc(F)c4Br)CC3)n2)cc1

nearest known ligand 0.33

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
OGA O60502 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.32
TP53 P04637 2/20 0.32
MAPT P10636 1/20 0.32
DNM1L O00429 5/20 0.31
HTR6 P50406 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
HRH3 Q9Y5N1 2/20 0.31
F2RL3 Q96RI0 1/20 0.31
AR P10275 1/20 0.30
KCNH2 Q12809 1/20 0.30
HRH4 Q9H3N8 1/20 0.30
MEN1 O00255 1/20 0.30
LMNA P02545 1/20 0.30
MAPK1 P28482 1/20 0.30
KMT2A Q03164 1/20 0.30
AOC3 Q16853 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3018237 0.93 AOC3 (0.33) OGASMN1; SMN2DNM1LHTR6NPC1
SCHEMBL3003296 0.93 DNM1L (0.34) SMN1; SMN2MAPTDNM1LHTR6NPC1
SCHEMBL3012451 0.91 MAPT (0.34) SMN1; SMN2MAPTNPC1RAB9AKCNH2
SCHEMBL3013236 0.91 NPC1 (0.36) SMN1; SMN2DNM1LNPC1RAB9AAR
SCHEMBL3011686 0.91 MAPT (0.35) SMN1; SMN2TP53MAPTHTR6NPC1
SCHEMBL3014046 0.91 F2RL3 (0.37) SMN1; SMN2TP53MAPTHTR6NPC1
SCHEMBL3008790 0.90 CACNA1G (0.33) SMN1; SMN2MAPTHTR6NPC1RAB9A
SCHEMBL3012892 0.90 DNM1L (0.32) SMN1; SMN2DNM1LHTR6NPC1RAB9A
SCHEMBL3010354 0.89 DNM1L (0.34) DNM1LHTR6HRH3F2RL3
SCHEMBL3013017 0.89 NPC1 (0.31) SMN1; SMN2DNM1LNPC1RAB9AHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA OGA 2888/4885SMN1; SMN2 1/4885TP53 2880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.